Allen Davidoff
Founder at XORTX THERAPEUTICS INC.
Net worth: 176 009 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul van Damme | M | - |
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | 6 years |
| Jim Fairbairn | M | 65 | 5 years | |
| William Farley | M | 68 | 3 years | |
| David G. Matthews | M | 62 |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | 6 years |
| Raymond Pratt | M | 73 | 3 years | |
| Nick Rigopulos | M | - | - | |
| Patrick Treanor | M | - | 1 years | |
| Daniel Feig | M | - |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | - |
| Henk ter Keurs | M | - |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | - |
| Stephen Haworth | M | - | 3 years | |
| Brian Mangal | M | - | - | |
| Michael D. Hill | M | - |
University of Calgary
| 25 years |
| Bruno M. Scherzinger | M | - |
University of Calgary
| 23 years |
| Anthony Giovinazzo | M | 67 | 2 years | |
| Charlotte May | F | - | - | |
| David MacDonald | M | - | 2 years | |
| Stacy Evans | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| W. Rowlands | M | 62 |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | 3 years |
| Allan Williams | M | 66 |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | 3 years |
| Douglas Janzen | M | 56 | 9 years | |
| Jackie Marie Clegg | F | 62 | - | |
| Alan Moore | M | - |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | 2 years |
| Anita Oliva | F | - |
University of Calgary
| 7 years |
| Ian Klassen | M | 57 | 3 years | |
| Jacqueline Le Saux | F | - | 2 years | |
| Patrick Lor | M | - |
University of Calgary
| 16 years |
| Jason Jogia | M | - |
University of Calgary
| 13 years |
| Harold Shlevin | M | 75 | 12 years | |
| Bruce G. Cousins | M | 63 | 2 years | |
| John Cameron Rewcastle | M | - |
University of Calgary
| 11 years |
| Sheila M. Grant | F | - | 17 years | |
| Paresh Chari | M | - |
University of Calgary
| 4 years |
| Gillian Wong-Hinds | F | - |
University of Calgary
| 4 years |
| Kristin Obreiter | F | 43 |
University of Calgary
| 4 years |
| Kelly Lo | F | - |
University of Calgary
| 4 years |
| Michael L. Stevens | M | - |
University of Calgary
| 4 years |
| Gavin Preston | M | - |
University of Calgary
| 4 years |
| Sean A. Kleiner | M | - |
University of Calgary
| 4 years |
| Feng Zhao | M | 60 |
University of Calgary
| 1 years |
| Monika Sumara | F | - |
University of Calgary
| 4 years |
| Jessica Gordon-Metez | F | - |
University of Calgary
| 4 years |
| Marina Post | F | - |
University of Calgary
| 4 years |
| Thomas Matthew | M | - |
University of Calgary
| 4 years |
| Derek T. Kreba | M | - |
University of Calgary
| 4 years |
| Mona Singh | F | - |
University of Calgary
| 4 years |
| Neil Korchinski | M | 47 |
University of Calgary
| 4 years |
| Dustin Ressler | M | - |
University of Calgary
| 4 years |
| Jeffrey Kearl | M | - |
University of Calgary
| 4 years |
| Chi Hang Lo | M | 45 |
University of Calgary
| 4 years |
| Anand Tanna | M | - |
University of Calgary
| 4 years |
| David Hawkins | M | - |
University of Calgary
| 13 years |
| Christi Hayes | F | - |
University of Calgary
| 4 years |
| David Alan Rassin | M | - |
University of Calgary
| 4 years |
| Carson Jing | M | - |
University of Calgary
| 4 years |
| Devin P. Mylrea | M | 57 |
University of Calgary
| 3 years |
| Grant McLeod | M | 46 |
University of Calgary
| 4 years |
| Mathew Roland Hermary | M | - |
University of Calgary
| 4 years |
| Cejay Kim | M | - |
University of Calgary
| 4 years |
| Gordon W. Howe | M | 49 |
University of Calgary
| 4 years |
| Charlotte Kristin Lindberg | F | 48 |
University of Calgary
| 1 years |
| Jeffrey Essel-Ampah | M | - |
University of Calgary
| 4 years |
| Douglas John Greig | M | 54 |
University of Calgary
| 4 years |
| Sarah Ann Mouritzen | F | - |
University of Calgary
| 2 years |
| Paul Surmanowicz | M | - |
University of Calgary
| 4 years |
| Ali Majid | M | - |
University of Calgary
| 4 years |
| Jerald D. Palmer | M | - |
University of Calgary
| 4 years |
| Dustin Daniel | M | - |
University of Calgary
| 3 years |
| James Newland Tanner | M | 71 |
University of Calgary
| 3 years |
| Peter Julien | M | - |
University of Calgary
| 4 years |
| Brian Gusko | M | 57 |
University of Calgary
| 2 years |
| Christopher F. M. Kemper | M | - |
University of Calgary
| 4 years |
| Julie B. Allan | F | - |
University of Calgary
| 4 years |
| George D. K. Yee | M | - |
University of Calgary
| 2 years |
| David M. la Rocque | M | - |
University of Calgary
| 2 years |
| Jeremy McCrea | M | - |
University of Calgary
| 4 years |
| Ada Litvinov | F | - |
University of Calgary
| 4 years |
| John J. Marshall | M | - |
University of Calgary
| 1 years |
| Heather Post | F | - |
University of Calgary
| 4 years |
| Jay Cerny | M | - |
University of Calgary
| 4 years |
| David James Ragan | M | - |
University of Calgary
| 4 years |
| Brian Glenn Purdy | M | - |
University of Calgary
| 2 years |
| Michael Harvey | M | - |
University of Calgary
| 4 years |
| Andrew Hamilton | M | 54 |
University of Calgary
| 2 years |
| Jamshed Khory | M | - |
University of Calgary
| 3 years |
| Chi Yan Lau | M | 49 |
University of Calgary
| 4 years |
| Daniel J. Dorland | M | - |
University of Calgary
| 4 years |
| Hugh M. Loney | M | 58 |
University of Calgary
| 4 years |
| Adam Deffett | M | 44 |
University of Calgary
| 4 years |
| Vanleo Y. W. Fung | M | 45 |
University of Calgary
| 4 years |
| Mona Jasinski | F | 60 |
University of Calgary
| 2 years |
| Grant James Hofer | M | - |
University of Calgary
| 4 years |
| Diana Chaw | F | - |
University of Calgary
| 5 years |
| Scott Bridge | M | - |
University of Calgary
| 2 years |
| Shannon L. Ouellette | F | - |
University of Calgary
| 1 years |
| Bryn O'Shaughnessy | M | - |
University of Calgary
| 12 years |
| Jarrett Bousquet | M | 48 |
University of Calgary
| 4 years |
| Sarah Tait | F | - |
University of Calgary
| 4 years |
| Eric Urzada | M | - |
University of Calgary
| 4 years |
| Mark Stevenson | M | - |
University of Calgary
| 4 years |
| Richard Tracy | M | - |
University of Calgary
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Allen Davidoff
- Personal Network
